Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies

作者全名："Lu, Yuting; Yuan, Xiangliang; Wang, Miao; He, Zhihao; Li, Hongzhong; Wang, Ji; Li, Qin"

作者地址："[Lu, Yuting; Wang, Miao; He, Zhihao; Li, Qin] Capital Med Univ, Beijing Friendship Hosp, Dept Oncol, Beijing 100050, Peoples R China; [Yuan, Xiangliang] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Lab Med, Sch Med, Shanghai 200025, Peoples R China; [Li, Hongzhong] Chongqing Med Univ, Chongqing Key Lab Mol Oncol & Epigenet, Affiliated Hosp 1, Chongqing 400010, Peoples R China; [Wang, Ji] Beijing Univ Chinese Med, Natl Inst TCM Constitut & Prevent Med, Beijing 100029, Peoples R China"

通信作者："Li, Q (通讯作者)，Capital Med Univ, Beijing Friendship Hosp, Dept Oncol, Beijing 100050, Peoples R China.; Wang, J (通讯作者)，Beijing Univ Chinese Med, Natl Inst TCM Constitut & Prevent Med, Beijing 100029, Peoples R China."

来源：JOURNAL OF HEMATOLOGY & ONCOLOGY

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:000788886800001

JCR分区：Q1

影响因子：28.5

年份：2022

卷号：15

期号：1

开始页：　

结束页：　

文献类型：Review

关键词：Cancer immunotherapy; Immune checkpoint inhibitors; Gut microbiota; Microbiota-derived metabolites; Therapeutic strategies

摘要："The gut microbiota have long been recognized to play a key role in human health and disease. Currently, several lines of evidence from preclinical to clinical research have gradually established that the gut microbiota can modulate antitumor immunity and affect the efficacy of cancer immunotherapies, especially immune checkpoint inhibitors (ICIs). Deciphering the underlying mechanisms reveals that the gut microbiota reprogram the immunity of the tumor microenvironment (TME) by engaging innate and/or adaptive immune cells. Notably, one of the primary modes by which the gut microbiota modulate antitumor immunity is by means of metabolites, which are small molecules that could spread from their initial location of the gut and impact local and systemic antitumor immune response to promote ICI efficiency. Mechanistic exploration provides novel insights for developing rational microbiota-based therapeutic strategies by manipulating gut microbiota, such as fecal microbiota transplantation (FMT), probiotics, engineered microbiomes, and specific microbial metabolites, to augment the efficacy of ICI and advance the age utilization of microbiota precision medicine."

基金机构："National Natural Science Foundation of China [81301912]; Beijing Municipal Health and Scientific and Technological Achievements and Appropriate Technology Promotion Project [BHTPP202008]; ""High-value Patent Cultivation""project of the Beijing Friendship Hospital Affiliated to the Capital Medical University [yyzscq202003]; Research Foundation of Beijing Friendship Hospital [yyqdkt2019-40]; General program of National Natural Science Foundation of China [81973715, 82174243]; Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine [ZYYCXTD-C-202001]"

基金资助正文：This work was supported by the National Natural Science Foundation of China (Grant No. 81301912); the Beijing Municipal Health and Scientific and Technological Achievements and Appropriate Technology Promotion Project (Grant No. BHTPP202008); the "High-value Patent Cultivation"project of the Beijing Friendship Hospital Affiliated to the Capital Medical University (Grant No. yyzscq202003); the Research Foundation of Beijing Friendship Hospital (Grant No. yyqdkt2019-40); the General program of National Natural Science Foundation of China (Grant No. 81973715 and 82174243); and the Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine (Grant No. ZYYCXTD-C-202001).